These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30392818)

  • 1. Pathogen reduction or inactivation technologies for platelet components: Does decision making have to await further clinical trials?
    Garraud O
    Transfus Apher Sci; 2018 Dec; 57(6):797-798. PubMed ID: 30392818
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of increased agitation speed on pathogen inactivation efficacy and in vitro quality in UVC-treated platelet concentrates.
    van der Meer PF; Gravemann U; de Korte D; Sumian C; Tolksdorf F; Müller TH; Seltsam A
    Vox Sang; 2016 Aug; 111(2):127-34. PubMed ID: 27167507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
    Lozano M; Cid J
    Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic Efficacy of Pathogen-Inactivated Blood Components.
    Ramsey G
    Semin Thromb Hemost; 2016 Mar; 42(2):172-82. PubMed ID: 26716500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peculiarities of studying the effects of pathogen reduction technologies on platelets.
    Osman A; Hitzler WE; Provost P
    Proteomics Clin Appl; 2016 Aug; 10(8):805-15. PubMed ID: 27095411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment.
    Schubert P; Culibrk B; Karwal S; Goodrich RP; Devine DV
    Proteomics Clin Appl; 2016 Aug; 10(8):839-50. PubMed ID: 27226085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
    Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
    Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology.
    Salunkhe V; De Cuyper IM; Papadopoulos P; van der Meer PF; Daal BB; Villa-Fajardo M; de Korte D; van den Berg TK; Gutiérrez L
    Platelets; 2019; 30(3):368-379. PubMed ID: 29553857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
    Seghatchian J; Tolksdorf F
    Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The platelets' perspective to pathogen reduction technologies.
    Osman A; Hitzler WE; Provost P
    Platelets; 2018 Mar; 29(2):140-147. PubMed ID: 28355122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.
    Prudent M; D'Alessandro A; Cazenave JP; Devine DV; Gachet C; Greinacher A; Lion N; Schubert P; Steil L; Thiele T; Tissot JD; Völker U; Zolla L
    Transfus Med Rev; 2014 Apr; 28(2):72-83. PubMed ID: 24685438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expired and Pathogen-Inactivated Platelet Concentrates Support Differentiation and Immunomodulation of Mesenchymal Stromal Cells in Culture.
    Jonsdottir-Buch SM; Sigurgrimsdottir H; Lieder R; Sigurjonsson OE
    Cell Transplant; 2015; 24(8):1545-54. PubMed ID: 25198449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen reduction technologies: The pros and cons for platelet transfusion.
    Magron A; Laugier J; Provost P; Boilard E
    Platelets; 2018 Jan; 29(1):2-8. PubMed ID: 28523956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose in platelet additive solutions: to add or not to add?
    Gyongyossy-Issa MI
    Transfus Apher Sci; 2011 Jun; 44(3):283-95. PubMed ID: 21493158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma.
    Kwon SY; Kim IS; Bae JE; Kang JW; Cho YJ; Cho NS; Lee SW
    Vox Sang; 2014 Oct; 107(3):254-60. PubMed ID: 24806328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of amotosalem treated platelets over 7 days of storage with an automated cytometry assay panel.
    Diquattro M; De Francisci G; Bonaccorso R; Tagliavia AM; Marcatti M; Palma B; Agliastro R
    Int J Lab Hematol; 2013 Dec; 35(6):637-43. PubMed ID: 23702080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.